Reshape Lifesciences INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
A group of investors led by Dominion Capital LLC has filed an amended Schedule 13D, disclosing a reduction in their beneficial ownership of ReShape Lifesciences Inc. common stock to 0.76%, triggering an exit filing.
SCHEDULE 13D: Investment Group Boosts Stake in ReShape Lifesciences to 9.9%, Backing Strategic Merger
A group of investors led by Dominion Capital LLC and Ascent Partners Fund LLC has increased its beneficial ownership in ReShape Lifesciences Inc. to 9.9%, signaling support for the company's strategic merger and providing potential future capital.